Xconomy: Drugs OK'd To Hit Tumor Genes Still a Basket of One. Are More Coming?

Xconomy: Drugs OK'd To Hit Tumor Genes Still a Basket of One. Are More Coming?

Drugs OK’d To Hit Tumor Genes Still a Basket of One. Are More Coming?

Alex Lash

May 31st, 2018

• @alexlash
• @xconomy
• Like Us

Xconomy National — 

[Corrected 6/4/18, 1:53 a.m. ET. See below.] One year ago, the FDA made biomedical history. A cancer drug, pembrolizumab (Keytruda), was approved to treat tumors with a specific genetic fingerprint regardless of their location in the body.